Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK21542 in Healthy Adult Male Volunteers.

Phase 1 Completed 6 enrolled Haisco Pharmaceutical Group Co., Ltd. The First Affiliated Hospital of Soochow University · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK21542 in healthy male subjects.

Timeline

Start: 2021-06-15
Primary completion: 2021-09-10
Completion: 2021-12-20

Publications

Yuan JJ, Bian YC, Ma S, Chen W, Zhang FY, Zhang H, Miao LY. Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in Humans. Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):723-731. doi: 10.1007/s13318-023-00858-0. Epub 2023 Oct 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK21542	Peptide	2 ug/kg	Intravenous

Indications

No indication recorded.